

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1011)

FURTHER DELAY IN DESPATCH OF CIRCULAR

Reference is made to (i) the announcement of China NT Pharma Group Company Limited (the “**Company**”) dated 11 November 2020 (the “**Announcement**”) in relation to, among other things, the disposal of the entire issued share capital of the Target Company; and (ii) the announcement of the Company dated 2 December 2020 in relation to the delay in despatch of the Circular (the “**Delay Announcement**”, together with the Announcement, the “**Announcements**”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

As disclosed in the Delay Announcement, a circular containing, among others, details of the Sale and Purchase Agreement and the transactions contemplated thereunder and other information as required under the Listing Rules together with the notice convening the EGM and the proxy form is expected to be despatched to the Shareholders on or before 23 December 2020 (the “**Circular**”).

As additional time is required for the Company to obtain the bank confirmations from the relevant banks in respect of the indebtedness position of the Company and its subsidiaries for the auditor to prepare the comfort letter relating to the statement of indebtedness for incorporation into the Circular, it is expected that the date of despatch of the Circular will be postponed from 23 December 2020 to a day falling on or before 13 January 2021.

By Order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman

Hong Kong, 23 December 2020

As at the date of this announcement, the executive Directors are Mr. Ng Tit, Ms. Chin Yu and Mr. Wu Weizhong; the non-executive Director is Dr. Qian Wei; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Mr. Pan Fei and Dr. Zhao Yubiao.